Myrobalan Therapeutics has been awarded a grant of more than $850,000 from the National Multiple Sclerosis Society to advance its new oral candidate MRO-002 for treating progressive forms of multiple… [+3399 chars]
Myrobalan wins grant for MS remyelination candidate MRO-002 - Multiple Sclerosis News Today
Myrobalan's experimental therapy MRO-002 is a GPR17 antagonist that's made to promote myelin repair in people with MS and other conditions.
By:Michela Luciano, PhD
Source:Multiple Sclerosis News Today
Published:
Related News
Intermountain Health offers 3 ways to reduce risk for cervical cancer - KSL.com
HPV vaccinations can help prevent cervical cancer, as well as a host of other cancers caused by HPV.
KSL.com•Intermountain LiveWell
Heart disease deaths declined. And here's how to reduce your risk of the #1 killer - NPR
An annual report from the American Heart Association shows deaths from heart disease and stroke are down, encouraging news after the rate went up in the early years of the pandemic.
NPR
A Rare, Deadly Fungus Is Making People Sick in Tennessee - Gizmodo
At least 36 cases of histoplasmosis and possibly one death have been reported in the state since last fall.
Gizmodo.com•Ed Cara